Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02145403 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
A Phase 1 study of Hematologic Malignancies and Graft-Versus-Host Disease, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT02145403 is a Phase 1 study of Hematologic Malignancies and Graft-Versus-Host Disease that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 53 participants, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02145403, a Phase 1 study of Hematologic Malignancies and Graft-Versus-Host Disease, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that adding carfilzomib to standard conditioning regimen for allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant relapse and treatment-related mortality by decreasing severe GVHD, leading to overall improvement in transplant outcomes.
Conditions Studied
Interventions
- DRUG Carfilzomib
- DRUG Tacrolimus
Study Locations (1)
Michigan
- University of Michigan Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2014-10 |
| Est. Completion | 2020-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02145403
The ClinicalTrials.gov registry entry for NCT02145403 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Carfilzomib is the first listed.
NCT02145403 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02145403 about?
NCT02145403 is a clinical study titled "Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies". The investigators hypothesize that adding carfilzomib to standard conditioning regimen for allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant relapse and treatment-related mortality by decreasing severe GVHD, leading to overall improvement in transplant outcome...
What is the current status of trial NCT02145403?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2014-10. Estimated completion is 2020-10-16.
What conditions does trial NCT02145403 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Graft-Versus-Host Disease, Relapse.
What interventions are being tested in trial NCT02145403?
The interventions under investigation include: Carfilzomib (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT02145403?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02145403 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.